share_log

Truist Securities Maintains Buy on Pacira BioSciences, Lowers Price Target to $55

Benzinga ·  Aug 3, 2023 12:10

Truist Securities analyst Les Sulewski maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $60 to $55.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment